Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Yasuko Nishimura"'
Autor:
Mika Mizuno, Kimihiko Ito, Hidekatsu Nakai, Hidenori Kato, Shoji Kamiura, Kimio Ushijima, Shoji Nagao, Hirokuni Takano, Masao Okadome, Munetaka Takekuma, Hideki Tokunaga, Satoru Nagase, Daisuke Aoki, Robert L. Coleman, Yasuko Nishimura, Christine K. Ratajczak, Hideyuki Hashiba, Hao Xiong, Noriyuki Katsumata, Takayuki Enomoto, Aikou Okamoto
Publikováno v:
International Journal of Clinical Oncology. 28:163-174
Background The phase 3 VELIA trial evaluated veliparib with carboplatin/paclitaxel and as maintenance in patients with high-grade serous ovarian carcinoma. Methods Patients with previously untreated stage III–IV high-grade serous ovarian carcinoma
Autor:
Noboru Asada, Jun Ando, Satoru Takada, Chikashi Yoshida, Kensuke Usuki, Atsushi Shinagawa, Kenichi Ishizawa, Toshihiro Miyamoto, Hiroatsu Iida, Nobuaki Dobashi, Sumiko Okubo, Hideyuki Honda, Tomomi Soshin, Yasuko Nishimura, Atsuko Tsutsui, Harumi Mukai, Kazuhito Yamamoto
Publikováno v:
Japanese Journal of Clinical Oncology.
Background In a Phase 3 international clinical trial (VIALE-C), venetoclax plus low-dose cytarabine improved the response rate and overall survival versus placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia who we
Autor:
Keisuke Ueki, Masayuki Kanamori, Hao Xiong, Yasuko Nishimura, Motoo Nagane, Yoshihiro Muragaki, Masakazu Yamada, Yoshitaka Narita, Kazuhiko Mishima, Masahide Matsuda, Katsunori Asai, Shota Kasai, Toshihiro Kumabe, Naoki Kagawa, Isao Date, Hiroyuki Kobayashi, Jun-ichiro Kuroda, Christopher Ocampo, Takaaki Beppu
Publikováno v:
Cancer Science
INTELLANCE‐J was a phase 1/2 study of a potent antibody‐drug conjugate targeting epidermal growth factor receptor (EGFR), depatuxizumab mafodotin (Depatux‐M), as a second‐ or first‐line therapy, alone or combined with chemotherapy or chemor
Autor:
Yasuhito Terui, Sumiko Okubo, Dai Maruyama, Ilseung Choi, Ahmed Salem, Yasuko Nishimura, Koji Izutsu, Su Young Kim, Koji Kato, Kazuhito Yamamoto, Noriko Fukuhara, Kathryn Humphrey, Takayuki Ishikawa, Natsumi Ogawa
Publikováno v:
International Journal of Hematology. 113:370-380
Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have limited treatment options. Venetoclax is a potent BCL-2 inhibitor that induces apoptosis in CLL cells. This open-label, phase 1/2 stud
Autor:
Hideyuki Honda, Wan Jen Hong, Sumiko Okubo, Yasuko Nishimura, Ahmed Salem, Noriko Fukuhara, Ilseung Choi, Jalaja Potluri, Takahiro Yamauchi, Shuichi Taniguchi, Kensuke Usuki
Publikováno v:
Japanese journal of clinical oncology. 51(6)
Background Venetoclax plus azacitidine is indicated in the USA for the treatment of newly diagnosed acute myeloid leukaemia in older patients (≥75 years) or those ineligible for induction chemotherapy due to co-morbidities. Methods In this phase 1/
Autor:
Yasuko Nishimura, Yutaka Yamanaka, Hideo Nakamura, Toshimasa Nishiyama, Ayako Kubota, Nobuyuki Mishima, Mari Miyake, Akemi Ota, Chika Sakurai
Publikováno v:
Journal of Occupational Safety and Health. 11:3-8
Autor:
Andreas Lazar, Ravi Shankar Prasad Singh, Roopal Thakkar, Anne M. Robinson, Yasuko Nishimura, Morio Ozawa, Kori Wallace, Nael M. Mostafa, Mamoru Watanabe, Yasuo Suzuki, Satoshi Motoya, Toshifumi Hibi
Publikováno v:
Inflammatory Intestinal Diseases. 2:228-235
Background: Dose escalation is often recommended for loss of response in anti-TNFα-treated patients with Crohn’s disease (CD). This 52-week phase 3, multicenter study investigated the efficacy and safety of escalation to adalimumab 80 mg every oth
Autor:
Yoshihiro Muragaki, Naoki Kagawa, Reiko Odagawa, Yasuko Nishimura, M. Matsuda, Kazuhiko Mishima, Yoshitaka Narita, Jun-ichiro Kuroda, Ikiru Matsumoto, Motoo Nagane, Kazuhiko Kurozumi, Katsunori Asai, Takashi Maruyama, Christopher Ocampo, Keisuke Ueki
Publikováno v:
Journal of Clinical Oncology. 37:2065-2065
2065 Background: The poor prognosis of glioblastoma (GBM; WHO grade IV) results from a high rate of disease recurrence and lack of effective treatment options. Depatuxizumab mafodotin (depatux-m, ABT-414) is comprised of an EGFR-directed antibody, de
Autor:
Kori Wallace, Anne M. Robinson, Toshifumi Hibi, Morio Ozawa, Roopal Thakkar, Satoshi Motoya, Samantha Eichner, Yasuko Nishimura, Mamoru Watanabe, Andreas Lazar
Publikováno v:
American Journal of Gastroenterology. 110:S795-S796
Autor:
YASUKO, NISHIMURA, YUTAKA, KUNIMATSU
Publikováno v:
京都府立大學學術報告. 農學 = The scientific reports of Kyoto Prefectural University. Agriculture. 42:13-18
有精卵と無精卵に対する洗卵処理が室温保存中の卵質に及ぼす影響について検討を行った。シェーバー・スタークロス288よりえた有精卵540個と無精卵540個を用い, その半数を台所用洗剤